About Acyl-CoA (8-3)-desaturase
Acyl-CoA (8-3)-desaturase (FADS1) is a protein
from Homo sapiens identified by UniProt accession
O60427, 444 residues long.
MolForge cross-references it against 0 known binders and
331 disease associations.
Target properties
| Protein name | Acyl-CoA (8-3)-desaturase |
| UniProt accession | O60427 |
| Gene | FADS1 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (331)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- Red cell distribution width · score 0.39
- serum metabolite measurement · score 0.39
- platelet count · score 0.39
- phosphatidylcholine measurement · score 0.38
- low density lipoprotein cholesterol measurement · score 0.36
- blood metabolite measurement · score 0.36
- glycerophospholipid measurement · score 0.34
- mean platelet volume · score 0.34
- lysophosphatidylcholine measurement · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60427-F1 | alphafold | PREDICTED | 94.40 | — |
Amino-acid sequence (444 residues)
MAPDPVAAET AAQGPTPRYF TWDEVAQRSG CEERWLVIDR KVYNISEFTR RHPGGSRVIS HYAGQDATDP FVAFHINKGL VKKYMNSLLI GELSPEQPSF EPTKNKELTD EFRELRATVE RMGLMKANHV FFLLYLLHIL LLDGAAWLTL WVFGTSFLPF LLCAVLLSAV QAQAGWLQHD FGHLSVFSTS KWNHLLHHFV IGHLKGAPAS WWNHMHFQHH AKPNCFRKDP DINMHPFFFA LGKILSVELG KQKKKYMPYN HQHKYFFLIG PPALLPLYFQ WYIFYFVIQR KKWVDLAWMI TFYVRFFLTY VPLLGLKAFL GLFFIVRFLE SNWFVWVTQM NHIPMHIDHD RNMDWVSTQL QATCNVHKSA FNDWFSGHLN FQIEHHLFPT MPRHNYHKVA PLVQSLCAKH GIEYQSKPLL SAFADIIHSL KESGQLWLDA YLHQ
Explore Acyl-CoA (8-3)-desaturase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets